Humana Inc. (NYSE:HUM) Shares Sold by ING Groep NV

ING Groep NV decreased its position in shares of Humana Inc. (NYSE:HUM) by 4.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,379 shares of the insurance provider’s stock after selling 724 shares during the quarter. ING Groep NV’s holdings in Humana were worth $3,902,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. AMF Tjanstepension AB increased its holdings in Humana by 166.8% in the third quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider’s stock valued at $12,686,000 after buying an additional 25,041 shares in the last quarter. Sequoia Financial Advisors LLC boosted its stake in shares of Humana by 3.2% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 2,408 shares of the insurance provider’s stock worth $763,000 after acquiring an additional 74 shares in the last quarter. Eastern Bank acquired a new stake in shares of Humana during the 3rd quarter valued at about $90,000. IFM Investors Pty Ltd increased its stake in shares of Humana by 0.5% in the 3rd quarter. IFM Investors Pty Ltd now owns 25,370 shares of the insurance provider’s stock valued at $8,036,000 after purchasing an additional 131 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in shares of Humana by 12.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 4,090 shares of the insurance provider’s stock valued at $1,295,000 after purchasing an additional 461 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Trading Down 5.7 %

Shares of HUM stock opened at $255.77 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The company’s 50-day moving average price is $269.41 and its 200-day moving average price is $290.00. The stock has a market cap of $30.80 billion, a price-to-earnings ratio of 25.71, a PEG ratio of 2.05 and a beta of 0.56.

Humana (NYSE:HUM) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.38%. Humana’s dividend payout ratio (DPR) is 35.58%.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Morgan Stanley dropped their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. JPMorgan Chase & Co. reduced their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Piper Sandler lifted their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $283.00 price target on shares of Humana in a research note on Wednesday, February 12th. Nineteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Humana currently has a consensus rating of “Hold” and an average price target of $285.68.

Insider Buying and Selling at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.32% of the company’s stock.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.